Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Jun;17(6):38.
doi: 10.1007/s11892-017-0865-4.

The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus

Affiliations
Review

The mTOR Signaling Pathway in Myocardial Dysfunction in Type 2 Diabetes Mellitus

Tomohiro Suhara et al. Curr Diab Rep. 2017 Jun.

Abstract

Purpose of review: T2DM (type 2 diabetes mellitus) is a risk factor for heart failure. The mTOR (mechanistic target of rapamycin) is a key mediator of the insulin signaling pathway. We will discuss the role of mTOR in myocardial dysfunction in T2DM.

Recent findings: In T2DM, chronically activated mTOR induces multiple pathological events, including a negative feedback loop that suppresses IRS (insulin receptor substrate)-1. While short-term treatment with rapamycin, an mTOR inhibitor, is a promising strategy for cardiac diseases such as acute myocardial infarction and cardiac hypertrophy in T2DM, there are many concerns about chronic usage of rapamycin. Two mTOR complexes, mTORC1 and mTORC2, affect many molecules and processes via distinct signaling pathways that regulate cardiomyocyte function and survival. Understanding mechanisms underlying mTOR-mediated pathophysiological features in the heart is essential for developing effective therapies for cardiac diseases in the context of T2DM.

Keywords: Cardiovascular disease; Cell signaling; Diabetes mellitus; Heart failure; Rapamycin; mTOR.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

Tomohiro Suhara, Yuichi Baba, Briana K. Shimada, Jason K. Higa, and Takashi Matsui declare that they have no conflict of interest.

Figures

Fig 1.
Fig 1.. Signaling pathways of mTOR complex activation and regulation.
AMPK, AMP-dependent protein kinase; DEPTOR, DEP-domain-containing mTOR interacting protein; elF4E, eukaryotic translation initiation factor 4E; ER, endoplasmic reticulum; FKBP12, FK506-binding protein 12kDa; Foxo1/3, forkhead box protein O 1/3; Grb10, growth factor receptor-bound protein 10; GSK-3β, glycogen synthase kinase 3β; IRS-1, insulin receptor substrate 1; mLST8, mammalian lethal with Sec 13 protein 8; mTOR, mechanistic target of rapamycin; mTORC1/2, mTOR complex 1 and 2; PDK1, phosphoinositide-dependent kinase 1; PI3K, phosphatidylinositol 3-kinase; PKC, protein kinase C; PRAS40, proline-rich Akt/PKB substrate 40 kDa; RAPTOR, regulatory associated protein of mTOR; RICTOR, rapamycin-insensitive companion of mTOR; Rheb, Ras homologue enriched in brain; SGK, serum- and glucocorticoid-regulated kinase; SIN1, stress-activated protein kinase-interacting protein; Tel2, telomere maintenance 2; TSC1/2, tuberous sclerosis complex 1 and 2; Tti1, Tel2 interaction protein 1; 4E-BP1, 4E-binding protein 1.

Similar articles

Cited by

References

    1. Writing Group M, Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation. 2016;133(4):e38–360. doi:10.1161/CIR.0000000000000350. - DOI - PubMed
    1. Fox CS, Coady S, Sorlie PD, D’Agostino RB Sr., Pencina MJ, Vasan RS et al. Increasing cardiovascular disease burden due to diabetes mellitus: the Framingham Heart Study. Circulation. 2007;115(12):1544–50. doi:10.1161/CIRCULATIONAHA.106.658948. - DOI - PubMed
    1. Shimobayashi M, Hall MN. Making new contacts: the mTOR network in metabolism and signalling crosstalk. Nat Rev Mol Cell Biol. 2014;15(3):155–62. doi:10.1038/nrm3757. - DOI - PubMed
    2. A comprehensive review of mTOR pathways, especially in metabolism and signaling crosstalk, providing new insight into the modulation of mTOR by other pathways.

    1. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res. 2007;100(7):1089–98. - PMC - PubMed
    1. Shende P, Plaisance I, Morandi C, Pellieux C, Berthonneche C, Zorzato F et al. Cardiac raptor ablation impairs adaptive hypertrophy, alters metabolic gene expression, and causes heart failure in mice. Circulation. 2011;123(10):1073–82. doi:10.1161/CIRCULATIONAHA.110.977066. - DOI - PubMed

MeSH terms

Substances